Quanterix(US:QTRX)2023-03-06 14:17Financial Performance & Guidance - Quanterix expects modest growth in 2023 and anticipates a return to double-digit growth by 2024[24] - The company aims to be cash flow positive at revenue between $170 million and $190 million in 2023[24] - Q4 2022 GAAP gross margin was 48.8%, while the non-GAAP gross margin was 41.3%[8, 12, 35] - Q4 2022 GAAP revenue was $25.8 million[8, 12, 35] - Quanterix anticipates GAAP gross margin in the mid-40s and non-GAAP gross margin in the low-40s for the end of 2023[2] - The company expects cash burn to improve by approximately 10% in 2023[2] Product & Scientific Advancements - Simoa pTau181 and NfL were associated with Alzheimer's Disease (AD) incidence within 9 years of diagnosis[31] - A study showed that 10 mg/kg of Leqembi every two weeks reduced mean plasma pTau-181 by 24% from baseline in 79 weeks[25] - Simoa GFAP was associated with clinical AD incidence 9 to 17 years before diagnosis[33] Revenue Streams - Lilly MCA (Master Collaboration Agreement) projects contributed to revenue, with a 28% increase[1, 20, 21] - The company estimates Lilly MCA license fee revenue between approximately $103 million and $109 million[1]